Insulet price target lowered to $325 from $360 at Piper Sandler

Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Insulet to $325 from $360 and keeps an Overweight rating on the shares. The company reported strong Q2 results and guidance was raised across nearly all metrics, the analyst tells investors in a research note. The firm recommends investors take advantage of the post-earnings weakness to build positions in the stock.